Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma PDF Print E-mail
Wednesday, 20 March 2013 15:00
Using the VivoSight OCT scanner, manufactured in the UK by Michelson Diagnostics Ltd, scientists at the Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds have developed the first quantitative imaging biomarker for skin involvement in Scleroderma.

Scleroderma or Systemic Sclerosis (SSc) is a serious type of autoimmune disorder affecting approximately 1 in 10,000 people. It is a progressive disease that involves skin and internal organs by determining fibrosis, vasculopathy and immune system activation.

The extent and severity of skin fibrosis is an important prognostic indicator of Scleroderma and often a primary endpoint in clinical trials to assess treatment efficacy. Skin fibrosis is currently assessed using a clinical semi-quantitative method called “modified Rodnan skin score”, based on clinical palpation in 17 body areas using a 0 to 3 scale. To develop their quantitative model, the group in Leeds led by Dr Francesco Del Galdo performed 458 OCT scans on 21 SSc patients, 1 morphea and 22 healthy controls, comparing the results with clinical assessment and histology.

Their results were recently published on the “Annals of the Rheumatic Diseases” Journal and also highlighted in this month issue of Nature Reviews Rheumatology. The authors conclude in their original work: “OCT of the skin could offer a feasible and reliable quantitative outcome measure in SSc. Studies determining OCT sensitivity to change over time and its role in defining skin vasculopathy may pave the way to defining OCT as a valuable imaging biomarker in SSc.”

The VivoSight OCT scanner enables clinicians to non-invasively image 1-2 mm beneath the surface of the skin with a clarity and accuracy previously unavailable. The research team in Leeds evaluated images captured of the dermal-epidermal junction and dermis using specially designed image processing algorithms. The significant correlation of the optical density with skin thickness and the excellent inter and intraobserver reliability of the technique suggests that an OCT-based algorithm is an accurate and reliable tool to quantify skin involvement in Scleroderma.

The study’s lead author Dr Giuseppina Abignano, who was recently awarded by the British Society for Rheumatology for her “illuminating research” with VivoSight said;

“Our study is the first in the field proposing a quantitative imaging biomarker of skin fibrosis in Scleroderma. We are currently undertaking a longitudinal study to test the sensitivity of the OCT based algorithm. These studies will tell us whether we can use OCT to determine changes in skin fibrosis over time and therefore use it as outcome measure in clinical trials and in clinical management. This is a very important step toward improving the prognosis for people who suffer from this devastating disease.”

Source: VivoSight (2013), "Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma"; original press release can be viewed here

 
More articles :

» Actelion Announces FDA Approval of Brand Name, Veletri, for Pulmonary Arterial Hypertension

US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for...

» Juvenile Localized Scleroderma: Fewer Flares With Methotrexate

was an effective and well-tolerated treatment for in a randomized, double-blind, placebo-controlled trial involving 70 patients with active disease. At the end of the 12-month study, 31 of 46 patients randomized to receive methotrexate had...

» Apoptosis Modulation as a Promising Target for Treatment of Systemic Sclerosis

St´ephane Chabaud and V´eronique J. MoulinReceived 1 June 2011; Revised 6 July 2011; Accepted 6 July 2011Systemic sclerosis (scleroderma, SSc) is a heterogeneous disease which develops into three forms: limited, intermediate, and diffuse. The...

» Scleroderma Drug In Development

According to , has partnered with , the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.The money will...

» Beta-thymosins and Interstitial Lung Disease: Study of a Scleroderma Cohort with a One-year Follow-up

Beta-thymosins play roles in cytoskeleton rearrangement, angiogenesis, fibrosis and reparative process, thus suggesting a possible involvement in the pathogenesis of systemic sclerosis. The aim of the study was to investigate the presence of...

» Platelet Gel In The Treatment Of Severe Scleroderma Skin Ulcers

Dilia Giuggioli, Michele Colaci, Andreina Manfredi, Mariateresa Mariano and Clodoveo FerriSystemic sclerosis (SSc) is characterized by microvascular damage and fibrosis of the skin and internal organs. Non-healing skin ulcers, mainly non-venous leg...